Mablink Bioscience is a French-based biotechnology company specialized in the development of an emerging class of cancer drugs, called antibody-drug conjugate (ADC). Mablink leverages its patented hydrophilic technology PSARlink™ that enables the design of homogenous, plasma-stable next generation ADCs with high DAR, whilst retaining excellent pharmacological properties, in order to quickly bring new and better treatment options to cancer patients.
Location: France, Auvergne-Rhône-Alpes, Lyon
Employees: 11-50
Total raised: $34.97M
Founded date: 2018
Investors 3
| Date | Name | Website |
| 21.03.2022 | Turenne Ca... | turennecap... |
| 27.04.2021 | Elaia Part... | elaia.com |
| 27.10.2022 | Korys | korys.be |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 14.10.2022 | Series A | $30.13M | - |
| 27.04.2021 | Seed | $4.84M | - |
Mentions in press and media 8
| Date | Title | Description |
| 18.09.2024 | Brenus Pharma: A New Dawn in Cancer Vaccines | In the world of biotechnology, every breakthrough is a beacon of hope. Brenus Pharma, a Lyon-based biotech company, has recently raised €22.2 million (approximately $25 million) in a Series A funding round. This infusion of capital is not j... |
| 18.09.2024 | Lyon-based Brenus Pharma raises €22.2 million for precision cancer vaccines | Brenus Pharma, a French biotech company specializing in the development of cancer vaccines, announced the completion of a €22.2 million Series A financing round. The round is led by Angelor, an investment fund bringing together a cluster of... |
| 13.03.2024 | As European dynamism gathers momentum, Elaia and partners double down with new deep tech fund | Deep tech is on the rise in Europe, fueled in part by the match between AI and a local flavor of math excellence. But it’s also benefiting from a growing community, public support and increasing amounts of funding. Elaia‘s third deep tech s... |
| 27.04.2021 | Mablink Bioscience : the next generation ADC company, raises 4 Million to move forward its ADC pipeline targeted at cancers with high unmet medical needs | LYON, France, April 27, 2021 /PRNewswire/ -- Mablink Bioscience, a company developing the next generation of antibody-drug conjugates (ADC) through its proprietary hydrophilic drug-linker PSARlink™ platform, announces today the completion o... |
| 27.04.2021 | Mablink Bioscience Raises €4M in Seed Funding | Mablink Bioscience, a Lyon, France-based company developing antibody-drug conjugates (ADC), completed a €4M seed financing round. The round was led by Elaia Partners with participation from Pertinence Invest 2 (Sofimac Innovation advised by... |
| 27.04.2021 | Mablink Bioscience, the next generation ADC company, raises €4 Million to move forward its ADC pipeline targeted at cancers with high unmet medical needs | |
| - | Mablink Bioscience, l’expert des ADC nouvelle génération, lève 4 Millions d’euros | (27/04/2020) Mablink Bioscience va développer son pipeline d’ADC dirigés contre des cancers avec peu ou pas d’options thérapeutiques satisfaisantes. Mablink Bioscience, une entreprise développant la nouvelle génération d’anticorps conjugué... |
| - | Mablink Bioscience | “Mablink develops antibody-drug conjugate (ADC) using its patented PSARlink™ technology to bring better treatment options to cancer patients.” |